Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Isavuconazonium→

Isavuconazonium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
742049-41-8
Molecular formula
C35H35F2N8O5S+
Molecular weight
717.8 g/mol
Drug class
Isavuconazole prodrugtriazole antifungal
Mechanism of action
Isavuconazonium is hydrolysed to isavuconazole, which inhibits fungal lanosterol 14-alpha-demethylase (CYP51), impairing ergosterol biosynthesis and fungal cell-membrane formation.
Indications / reported uses
  • Treatment of invasive aspergillosis in adults
  • Treatment of invasive mucormycosis in adults; use is product-label specific and should be directed by specialist infectious-disease care

Sources: US DailyMed — CRESEMBA (isavuconazonium sulfate) · EMA EPAR — Cresemba · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Isavuconazonium Environmental Risk Assessment (ERA) (the Isavuconazonium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.